MXCT Insider Purchase Raises Director Ownership to 398,328 Shares

Rhea-AI Filing Summary

Erck Stanley C, a director of MaxCyte, Inc. (MXCT), purchased 100,000 shares of the company’s common stock on 08/13/2025. The Form 4 shows the purchases were coded as P (purchase) and were made at prices ranging from $1.29 to $1.44, with a reported price entry of $1.3722. After the transactions the reporting person directly beneficially owned 398,328 shares. The filer notes the shares were bought in multiple transactions and offers to provide a detailed breakdown of the number of shares bought at each price upon request. No derivative holdings are reported on the form.

Positive

• Director purchase of 100,000 shares demonstrates insider acquisition reported on Form 4
• Direct beneficial ownership increased to 398,328 shares, disclosed explicitly
• Purchase price range disclosed ($1.29–$1.44) and an aggregate price entry of $1.3722
• Filer offers to provide detailed price breakdowns for the multiple execution prices

Negative

• None.

Insights

Securities Analyst

Director purchased 100,000 MXCT shares at low-single-digit dollar prices; increases direct holding to 398,328 shares.

The Form 4 documents a straightforward open-market purchase coded as a purchase (P) on 08/13/2025 totaling 100,000 common shares at prices between $1.29 and $1.44, with an indicated price of $1.3722. The increase in direct beneficial ownership to 398,328 shares is factual and verifiable from the filing. This transaction is a clear insider buy but its materiality relative to company capitalization cannot be assessed from the form alone.

Corporate Governance Expert

A director-level open-market purchase is reported; disclosure is complete with a footnote offering granular price details.

The filing identifies the reporting person as a director and discloses a purchase across multiple executions with a disclosed price range and an asserted aggregate price entry of $1.3722. The form is signed by an attorney-in-fact, and the filer commits to provide underlying execution price details if requested. From a governance perspective, the filing meets Section 16 disclosure requirements without indicating any loan, grant, or derivative arrangements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Erck Stanley C

(Last) (First) (Middle)

C/O MAXCYTE, INC.

9713 KEY WEST AVENUE, SUITE 400

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MAXCYTE, INC. [ MXCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2025		P		100,000	A	$1.3722(1)	398,328	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were purchased in multiple transactions at prices ranging from $1.29 to $1.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ David Sandoval, Attorney-in-Fact	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Erck Stanley C report for MXCT?

The Form 4 reports a purchase of 100,000 common shares of MaxCyte on 08/13/2025 (transaction code P).

At what prices were the MXCT shares purchased?

The shares were bought at prices ranging from $1.29 to $1.44, with a reported price entry of $1.3722; the filer says purchases occurred in multiple executions.

How many MXCT shares does the reporting person own after the transaction?

Following the reported transactions the reporting person directly beneficially owned 398,328 shares.

Does the Form 4 report any derivative securities for MXCT?

No. Table II contains no derivative securities reported in this filing.

Who signed the Form 4 filing for this transaction?

The form is signed by David Sandoval, Attorney-in-Fact on behalf of the reporting person.